Receive our newsletter – data, insights and analysis delivered to you
  1. Special Focus
  2. Covid-19
April 21, 2020

Covid-19: Healthcare daily update – two thirds of cases may be undiagnosed – pandemic impacting on clinical trials in neurology

By Paul Dennis

Two-thirds of Covid-19 cases may be undiagnosed: modelling estimate based on real-world data
Based on modelling assumptions using available data to date, GlobalData estimates that 50–80% of the Covid-19 cases are mild and asymptomatic and thus not likely to be diagnosed. It is paramount that undiagnosed cases of Covid-19 are mapped quickly to accurately predict the number of asymptomatic contagious cases.

Moderna’s Phase I Covid-19 mRNA vaccine has manufacturing edge but many obstacles to confirm protection lie ahead
Moderna Phase I mRNA-1273 vaccine drew cautious reviews on its potential to trigger immunogenicity for protection against Covid-19. From using mRNA as a vaccine strategy, to the antigen choice of the virus’ spike protein, interviewed experts noted several advantages but in the same breath voiced many concerns.

 

Athersys’, Pluristem’s and Mesoblast’s mesenchymal stromal cell therapies vie for efficacy in Covid-19
Mesenchymal stromal cell (MSC) therapies have experts noting that the field is still grappling with questions on the ideal source for MSCs and optimal dosing strategies. Hence, calling a potential winner between the three key players, Athersys, Mesoblast and Pluristem Therapeutics, is tough. Also, unlike biologics or antivirals being tested in Covid-19, the ability to scale-up manufacturing will be a critical component if MSCs are to be a panacea to all patients with Covid-related acute respiratory distress syndrome (ARDS).

 

Risk assessment of Covid-19 on patients suffering from IBD
The BSG consensus advice for the management of IBD during the Covid-19 pandemic suggests patients with severe symptoms will continue to be assessed in a location away from Covid-19 assessment areas. However, in order to reduce traffic in outpatient clinics, mild IBD patients will be deferred to a telemedicine system, which will be adopted to conduct appointments and review new IBD patients.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

 

Impact of Covid-19 pandemic on clinical trials evaluating various neurology indications
According to GlobalData’s Intelligence Center, a total of 81 trials with a definite neurology indication were identified as those impacted by the Covid-19 pandemic as of 15 April. Of these trials, indications related to pain and mental health are the most dominant, with the former accounting for 21% and the latter accounting for 19%.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU